Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis.

Journal: Clinical therapeutics

PMID: 29287749

Abstract

PURPOSE: Andecaliximab (GS-5745) is a highly selective monoclonal antibody against matrix metalloproteinase-9 (MMP9), a proteolytic enzyme implicated in the pathogenesis of rheumatoid arthritis (RA). This study assessed the safety and pharmacokinetic (PK) parameters of andecaliximab in patients with RA and evaluated the effects of andecaliximab treatment on exploratory disease biomarkers.

Authors

David L Gossage

Gilead Sciences, Inc, Foster City, California, USA. Electronic address: david.gossage@gilead.com.
Blanka Cieslarová

Pharmaceutical Research Associates, CZ, s.r.o., Prague, Czech Republic.
Sophe Ap

Gilead Sciences, Inc, Foster City, California, USA.
Hao Zheng

Gilead Sciences, Inc, Foster City, California, USA.
Yan Xin

Gilead Sciences, Inc, Foster City, California, USA.
Preeti Lal

Gilead Sciences, Inc, Foster City, California, USA.
Guang Chen

Gilead Sciences, Inc, Foster City, California, USA.
Victoria Smith

Gilead Sciences, Inc, Foster City, California, USA.
John S Sundy

Gilead Sciences, Inc, Foster City, California, USA.

Keywords

Aged Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antirheumatic Agents Arthritis, Rheumatoid Double-Blind Method Female Humans Infusions, Intravenous Male Matrix Metalloproteinase 9 Matrix Metalloproteinase Inhibitors Middle Aged

External Resources

View on PubMed Access via DOI PubMed (29287749)

Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals